|Videos|August 24, 2022
Patient Eligibility and Logistical and Safety Considerations for Tebentafusp Treatment in mUM
Author(s)Sunandana Chandra, MD, MS
An oncologist outlines which patients with mUM are eligible for bispecific T-cell receptor immunotherapy, discusses logistical and safety considerations, and explains why pre-treatment HLA testing is required for those considering the regimen.
Advertisement
Episodes in this series
Advertisement
Related Content
Advertisement
Advertisement
Trending on CURE
1
Balance Exercises for Patients With Cancer: How the Single-Leg Stand Builds Stability
2
Clock Touches: An Advanced Balance Exercise for Patients with Cancer
3
Wildfire Smoke and Cancer Risk: What Patients Should Know
4
Family History of Cancer Fuels Oncology Nurse's Passion for Patient Care
5